Navigation Links
Clinical Renal Trails Do Not Have Sufficient Women Participants

New findings that are being presented during the American Society of Nephrology’s 38th Annual Meeting and Scientific Exposition in Philadelphia, Pennsylvania, say that women are not being adequately represented during medical trials // more specifically renal trials. Through analyses of the recently conducted renal trials showed this shortcoming.

It is theorized that this may be the reason why the US Food and Drug Administration (FDA) decided to withdraw many of these drugs from the market. It was found that over the last ten years, 8 out of 10 drugs that were ordered to be withdrawn had serious side effects in women. Dr. Julia Lewis of Vanderbilt University’s Division of Nephrology says that even with the above evidence women were underrepresented at clinical renal trials that were conducted to test the efficacy of certain drugs. She will speak at the symposium and say that pathogenesis of progressive renal disease and hypertension is dependent to some extent on sex hormones and ignoring these potentially harmful effects could adversely impact the health of women. Dr. Lewis is scheduled to speak at length on a topic titled “Gender Issues in Large Clinical Renal Trials,” during a symposium entitled, The Pathophysiology of Progressive Renal Disease and Hypertension: Importance of Gender and Ethnicity.

The meeting is being held from November 8-13 at the Pennsylvania Convention Center in Philadelphia, PA and focuses on distributing the latest research and clinical findings on kidney diseases among 12,000 nephrologists who assemble at the gathering
'"/>




Page: 1

Related medicine news :

1. Clinical trials need to be more frank
2. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
3. The Growing Rise In Clinical Research Could Lead To A Compromise In Quality Of Research And Ethics
4. Clinical Comparisons Between ADHD Drugs Are Less
5. A Novel System For Clinical Banking Of Umbilical Cord Blood
6. Clinical Trials of New Drug Febuxostat Show Promise in Gout Treatment
7. Clinical Trials Of New Anti-Cancer Drug To Be Initiated In New Zealand
8. Green Tea Consumption Found To Improve Clinical Outcome In Cancer Patients
9. Cancer Clinical Research in India
10. New Generation Clinical Trials Could Save Time And Money, Improve Patient Care
11. Clinical Impact of Activity and Abdominal Pressure on Pelvic Floor Dysfunction Need to Be Further Analyzed
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/29/2016)... ... April 29, 2016 , ... Mobility Designed is redefining mobility ... the armpits, the M+D Crutch evenly distributes body weight from the elbow to the ... when using the crutches than with other crutches. , Co-founders Max and Liliana Younger ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... Association (CCA), is pleased to announce the launch of the GFCP Scoop ... recipes, and more. The purpose of the GFCP Scoop site is ...
(Date:4/29/2016)... ... ... Dr. Robert Mondavi, one of the dentists in Torrance , is now ... as more patients are discovering the many different ways they can change and improve ... to them and which ones might work for their smiles. , “One of ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Reltok Nasal Products ... products for the head and neck/ear, nose and throat specialty, has added the KOTLER ... The KOTLER NASAL AIRWAY™ is a newly patented safety device secured by nasal ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the market leader ... led by Eastside Partners, with participation from existing investor Martin Ventures. The ... accelerate its technology and product roadmap. , “Jvion is experiencing significant ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... 27, 2016  Hologic, Inc. (Nasdaq: ... for the fiscal second quarter ended March 26, ... $0.24 increased 41.2%, and non-GAAP diluted EPS of ... 5.8% on a reported basis, and 6.3% on ... posted another good quarter, highlighted by 14.6% growth ...
(Date:4/27/2016)... , le 27 Avril 2016 ... a progressé de +5% sur le trimestre, soutenu ... de consommables  Croissance de +16% des ... Mauna Kea Technologies (Euronext : MKEA, FR0010609263 ; ... confocale laser, annonce aujourd,hui son chiffre d,affaires pour ...
(Date:4/27/2016)... 2016 Elekta today announced that ... be the focal point of seven scientific presentations at ... for Radiotherapy & Oncology, taking place April 29 - ... radiotherapy system and a high-field MRI scanner with sophisticated ... patient,s anatomy in real time. The MR-linac is designed ...
Breaking Medicine Technology: